NCT00119249View on ClinicalTrials.gov

Sorafenib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery

PHASE2CompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

November 30, 2007

Conditions
Stage III MelanomaStage IV Melanoma
Interventions
DRUG

sorafenib tosylate

Given orally

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

10467-2490

Montefiore Medical Center, The Bronx

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00119249 - Sorafenib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery | Biotech Hunter | Biotech Hunter